Botulinum Toxin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Botulinum Toxin Market is Segmented by Application (Cosmetic Applications, Non-cosmetic Applications), End-User (Spas and Beauty Centers and Clinics and Hospitals), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Botulinum Toxin Market Summary
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.5 %
Botulinum Toxin Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Botulinum Toxin Market was valued at USD 4,655.53 million in 2021, and it is expected to reach USD 8.572.77 million by 2027, registering a CAGR of 9.5% during the forecast period.

The cosmetic and aesthetic fillers manufacturers had to shut down the production and supply units due to the lockdown, that was imposed in the beginning of COVID-19 outbreak, worldwide. According to the article “Impact of COVID-19 outbreak on plastic surgery: Taken precautions, distribution of surgical procedures and changes in admissions to outpatient clinic,” published in April 2021, when compared to the routine period, there was a general decrease in consultations from other clinics to plastic surgery clinic from 548 to 201 in the pandemic period. Additionally, consumers were also looking for online cosmetic home treatments. Thus, the cosmetic brands used this opportunity to renovate their online offerings, to offer e-consultation services, and invest in the right technology, such as chatbots and augmented/virtual reality, as more consumers seek cosmetic advice from the comfort of their home during the pandemic, which reduced the risk of being infected. Thus, COVID-19 has highly impacted the botulinum toxin market worldwide. However, the situation is gradually improving.

The growth of the global botulinum toxin market is currently being driven by various factors. These include the increasing demand for aesthetic procedures, growing research and development initiatives to expand the therapeutic applications of botulinum toxin, and growing patient preference for non-invasive or minimally treatments, coupled with novel products' development. For instance, according to “PLASTIC SURGERY STATISTICS 2020 REPORT,” published in the American Society of Plastic Surgeons, around 4,401,536 Botulinum Toxin Type A minimally-invasive procedures were performed in 2020, a 13% decrease from the Botulinum Toxin Type A procedures performed in the previous year. The decline in the number of surgeries is due to the strict rules imposed by governments across different countries due to the COVID pandemic, which highly affected the studied market.

The increasing quality of care improved professional services, and the availability of minimally invasive surgeries by highly qualified aesthetic surgeons have contributed to the growth of procedural volume. Furthermore, technological advancements, the introduction of cost-effective aesthetic products, the aging population, and rising incidence of aesthetic problems, such as crow’s foot and lateral canthal lines are also boosting the growth of the botulinum toxin market globally. For instance, in January 2021, Maypharm launched new botulinum toxin, METOX which is an effective solution for smoothing any kind of wrinkles from severe to moderate, caused by daily active facial movements. In the recent years, patients are demanding a wide range of products to treat more and more facial areas, which is increasing the average amount of time and money spent on each patient in clinics globally. Hence, due to the increasing demand and urge to look attractive, these procedures are largely performed by celebrities and their fans, owing to huge media coverage, making it more socially acceptable. However, the side effects of available products, lack of reimbursement policies supporting cosmetic procedures, and the high cost of the products can limit the adoption rate of botulinum toxin during the forecast period.

Scope of the Report

As per the report's scope, botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum. As a result, highly diluted concentrations of botulinum toxin are used for cosmetic and non-cosmetic purposes, such as for the treatment of frown lines between the eyebrows, dystonia, chronic migraine, and other purposes. Botulinum Toxin Market is Segmented by Application (Cosmetic Applications, Non-cosmetic Applications), End-User (Spas and Beauty Centers and Clinics and Hospitals), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Application
Cosmetic Applications
Glabellar lines
Lateral canthal lines (crow's feet)
Forehead Lines
Other Cosmetic Applications​
By Non-Cosmetic Applications
Chronic migraine
Ophthalmologic disorders
Other Non-cosmetic Applications
By End User
Spas and Beauty Centers
Clinics and Hospitals
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cosmetic Applications Segment Holds Significant Share

There is a rising demand for aesthetic appearance among the individuals that have created a subsequent demand for botulinum toxin procedures around the world. The concerns of people regarding their appearance are gradually on the increase, both in the developed and the developing world; thus, there is an increase in the number of cosmetic surgeries done, annually.

According to the American Society of Plastic Surgeons' (ASPS) recent data, among the 2,630,832 cosmetic non-invasive procedures performed in the United States in 2019, botulinum toxin Type A tops the list with 1,301,823 procedures. The botulinum toxin injection for the treatment of wrinkles is one of the most frequently performed cosmetic procedures worldwide, and it is one of the most common entry procedures for clinicians who seek to incorporate aesthetic treatments into their practice.

Globally, the increasing demand for modern beauty standards has created a massive growth platform for botulinum toxin A products across the world. Furthermore, therapeutic applications for botulinum toxins have opened the doors for growth through the healthcare platform.

According to the National Clinical Trial (NCT) Registry, as of 18 June 2021, there are more than 312 ongoing and planned clinical trials related to botulinum toxin A across different development phases for various indications. Moreover, In March 2021, Revance announced that the long-awaited, longer-lasting neuromodulator drug candidate DaxibotulinumtoxinA for Injection (DAXI), a botulinum toxin type A formulated with a novel peptide excipient or combined treatment of glabellar, dynamic forehead, and lateral canthal lines is nearing the FDA approval. In December 2020, the company announced the results from its phase 2 upper facial lines study investigating DAXI. These factors are expected to impact the market positively in the future.

Botulinum Toxin Market: Total Procedures Conducted with Botulinum Toxin Type A, By Sex, United States, 2020

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the global market. The medical aesthetic technology has advanced rapidly over the last two decades in the region. The highly advanced technologies have offered a wide range of products and solutions to patients seeking medical assistance.

For instance, according to “PLASTIC SURGERY STATISTICS 2020 REPORT,” published in the American Society of Plastic Surgeons, there were around 13.2 million cosmetic minimally-invasive procedures performed in the United States in 2020 wherein Botulinum Toxin Type A contributed to around 33% share of the total cosmetic minimally-invasive procedures performed in the country thus increasing the demand of the studied market in the forecast period.

There is also competition in the United States botulinum toxin market that is expected to grow with the launch of Allergan's BOTOX, which received Food and Drug Administration (FDA) approval in July 2021, which included eight new muscles for the treatment of upper limb spasticity in adults. The FDA approval not only adds to the company's rich history in neurotoxin science but also reinforces the role of BOTOX in upper limb spasticity treatment as it provides an evidence-based dosing strategy to meet the clinical needs of providers and their patients, thus increasing the demand for the studied market in the United States.

Also, In April 2021, Aquavit Holdings LLC announced that it acquired an exclusive license to register, market, and commercialize a botulinum toxin (DTX-021) in the United States and Canada.Hence, all these approvals and launches helped in the growth of the overall market and is expected to continue the same trend over the forecast period.

Botulinum Toxin Market - Growth Rate by Region

Competitive Landscape

Botulinum Toxin market has rapidly evolved over the last few years. Industry observed significant changes in adopting market strategies such as product developments, mergers, and acquisitions in recent years. Thus, the Botulinum Toxin market has become a very competitive industry. Major companies in the market are Galderma, Evolus, Inc., Merz Pharma GmbH & Co. KGaA, AbbVie Inc. (Allergan), Ipsen Pharma among others.

Major Players

  1. Evolus, Inc.

  2. AbbVie Inc. (Allergan)

  3. Merz Pharma GmbH & Co. KGaA

  4. Ipsen Pharma

  5. Galderma

Botulinum Toxin Market Concentration

Recent Developments

  • In July 2022, Swiss biotech Fastox Pharma presented its groundbreaking long-lasting botulinum toxin LAST technology at the leading conference on neurotoxins. Fastox has discovered that combining botulinum toxin type A (BoNT/A) with fast-acting myorelaxant drugs is anticipated to accelerate BoNT/A onset of action.
  • In April 2021, Aquavit Holdings LLC acquired an exclusive license to register, commercialize and market its botulinum toxin (DTX-021) in the United States and Canada.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Demand for Aesthetic Procedures

      2. 4.2.2 Growing Research and Development Initiatives to Expand the Therapeutic Applications of Botulinum Toxin

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse effects Associated with Botulinum Toxin

      2. 4.3.2 Lack of Reimbursement Policies Supporting Cosmetic Procedures

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 5.1 By Application

      1. 5.1.1 Cosmetic Applications

        1. Glabellar lines

        2. Lateral canthal lines (crow's feet)

        3. Forehead Lines

        4. Other Cosmetic Applications​

      2. 5.1.2 By Non-Cosmetic Applications

        1. Dystonia

        2. Chronic migraine

        3. Ophthalmologic disorders

        4. Other Non-cosmetic Applications

    2. 5.2 By End User

      1. 5.2.1 Spas and Beauty Centers

      2. 5.2.2 Clinics and Hospitals

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Merz Pharma GmbH & Co. KGaA

      2. 6.1.2 AbbVie Inc. (Allergan)

      3. 6.1.3 Galderma

      4. 6.1.4 Evolus, Inc.

      5. 6.1.5 Revance Therapeutics Inc.

      6. 6.1.6 HUGEL, Inc.

      7. 6.1.7 Ipsen Pharma

      8. 6.1.8 US WorldMeds LLC

      9. 6.1.9 Medytox

      10. 6.1.10 Eisai

      11. 6.1.11 Hugh Source International

      12. 6.1.12 Galderma

      13. 6.1.13 Daewoong Pharmaceuticals

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Botulinum Toxin Market market is studied from 2019 - 2027.

The Global Botulinum Toxin Market is growing at a CAGR of 9.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Evolus, Inc., AbbVie Inc. (Allergan), Merz Pharma GmbH & Co. KGaA, Ipsen Pharma, Galderma are the major companies operating in Global Botulinum Toxin Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!